HyperAcute®-Pancreas
A Phase 2, single-arm, open-label study is currently enrolling patients at multiple clinical trial sites. Patients with newly diagnosed Stage I or II pancreatic carcinoma who have undergone surgical tumor resection within six weeks prior to enrollment receive a gemcitabine-plus-chemoradiation regimen plus HyperAcute-Pancreas immunotherapy. The primary objective of this Phase 2 study is to assess disease-free survival.
For information on eligibility criteria, study specifics, and a list of enrolling sites, click here.
An additional Phase 2, double-arm, open-label, non-randomized study is currently enrolling patients at University of Louisville in Louisville, Kentucky. Eligible patients have newly diagnosed Stage I or II pancreatic carcinoma and have undergone surgical tumor resection within six weeks prior to enrollment. One group of patients receives a gemcitabine-plus-chemoradiation regimen plus HyperAcute-Pancreas immunotherapy. The second group, comprising patients who refuse or cannot tolerate chemotherapy/radiation, receives only Hyper-Acute-Pancreas immunotherapy. The primary objective of this Phase 2 study is to assess disease-free survival.
For information on eligibility criteria, study specifics, and contact information, click here